Aquestive Q4 2025 slides detail FDA setback, resubmission plan
#Aquestive #FDA #Q4 2025 #setback #resubmission #regulatory #pharmaceutical #approval
📌 Key Takeaways
- Aquestive faced an FDA setback for a product in Q4 2025.
- The company detailed the setback and a resubmission plan in its slides.
- The resubmission plan aims to address FDA concerns for approval.
- The news highlights regulatory challenges in pharmaceutical development.
🏷️ Themes
Regulatory Setback, Pharmaceutical Strategy
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with Brent up about 15% Gold slips slightly lower; stronger U.S. dollar weighs Iran conflict latest: Israel, Iran exchange strikes as fighting enters sixth day UBS sees limited upside for silver prices over the next 12 months (South Africa Philippines Nigeria) Aquestive Q4 2025 slides detail FDA setback, resubmission plan By Company News Published 03/05/2026, 10:23 AM Aquestive Q4 2025 slides detail FDA setback, resubmission plan 0 AQST -2.63% Introduction & Market Context Aquestive Therapeutics (NASDAQ:AQST) presented its fourth quarter and full year 2025 earnings results on March 5, 2026, detailing the company’s response to a regulatory setback for its lead product candidate while reporting mixed financial performance. The stock declined 3.89% in premarket trading to $4.20, extending losses from the previous session’s 3.09% drop, as investors digested both an earnings miss and the Complete Response Letter received from the FDA for Anaphylm. The company reported Q4 2025 revenue of $13 million, representing 10% year-over-year growth but falling short of analyst expectations of $13.34 million. Earnings per share came in at -$0.26, missing the forecasted -$0.13 loss by 100%, largely due to elevated legal expenses that pushed selling, general and administrative costs to $32.8 million compared to $16 million in the prior year period. Quarterly Performance Highlights The company’s earnings presentation outlined key achievements and challenges from the quarter. As detailed in the following summary of strategic priorities, Aquestive ended 2025 with approximately $121 million in cash and cash equivalents, providing financial runway into 2027 to complete the Anaphylm approval process. Manufacturing operations continued to generate revenue growth, with doses shipped reaching 47,250 in Q4 2025, the highest quarterly volume in recent periods and a significant increase f...
Read full article at source